Remdesivir for the Treatment of Covid-19 — Final Report

20207,680 citationsJournal Articlegreen Open Access

Authors

John H. Beigel · National Institute of Allergy and Infectious Diseases

Kay M Tomashek · National Institute of Allergy and Infectious Diseases

Lori E. Dodd · National Institute of Allergy and Infectious Diseases

Aneesh K. Mehta · National Institute of Allergy and Infectious Diseases

Barry S. Zingman · National Institute of Allergy and Infectious Diseases

André C. Kalil · National Institute of Allergy and Infectious Diseases

Abstract

Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTT-1 ClinicalTrials.gov number, NCT04280705.).

Topics & Keywords

COVID-19 Clinical Research Studies Long-Term Effects of COVID-19 SARS-CoV-2 and COVID-19 Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 383, Issue 19, pp. 1813-1826

DOI: 10.1056/nejmoa2007764

Field-Weighted Citation Impact: 172.36